# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-26T23:59:41.418838

---

**Idea Fidelity**  
The paper adheres closely to the manifest. It exploits the EGRRCPA threshold shift ($1B\to \$3B$) to isolate banks newly eligible for 18-month exam cycles, contrasts them with nearby larger banks that remained on 12-month cycles, and leverages FDIC call report data—exactly as outlined. The treatment definition, sample window (2016Q1–2023Q4), outcomes (noncurrent loans, capital, loan composition), and robustness checks (placebo, donut-hole, COVID restriction) all mirror the proposed strategy. No key element of the identification plan or empirical setup described in the manifest is missing in the paper.

**Summary**  
The paper studies whether extending bank examination cycles from 12 to 18 months for well-capitalized community banks (those with \$1–3 billion in assets) under EGRRCPA led to greater risk-taking, using a difference-in-differences design against \$3–\$10 billion banks. With 32 quarters of FDIC call report data, the author finds no economically meaningful increase in noncurrent loan ratios, capital erosion, or compositional risk-taking among treated banks. A battery of robustness checks—placebo, donut-hole, pre-COVID subsamples—reinforces the null, suggesting market discipline/internal governance may substitute for exam frequency.

**Essential Points**

1. **Interpretation of a Precise Null:** The paper’s centerpiece is a null finding. Nulls are credible only with high statistical power and transparent reporting of minimal detectable effects. While the summary statistics and event study suggest reasonable balance, the paper should present formal power calculations (or equivalently, minimum detectable effect sizes) for the noncurrent loan ratio and other outcomes. Without this, it is hard to judge whether the study was “powered” to detect economically meaningful increases in risk. Relatedly, the paper reports a 95% confidence interval only implicitly—explicitly stating the bounds on the post/pre difference would clarify whether even moderate increases are ruled out.

2. **Treatment Timing / Measurement Uncertainty:** The paper assumes immediate treatment in 2018Q3, but the interim rule (Aug 29, 2018) may have allowed for phased implementation depending on exam scheduling and CAMELS evaluations. Banking examinations are not strictly time-synchronized; a bank could have been examined 11 months after the last visit and may not immediately experience an 18-month cycle. This raises concerns about treatment intensity and timing. The authors should provide more discussion or evidence on when banks actually shifted to 18-month exams (e.g., actual on-site exam dates in regulatory releases if available, or at least whether any banks continued to see 12-month exams for some time). Without verifying that the policy change actually generated the intended “deterrence gap” across treated banks, the DiD estimates may be attenuated.

3. **Control Group Validity and Potential Size Trends:** While banks above \$3B provide a natural comparison, they are systematically larger and may face different market or macro shocks. Although the event study displays flat pre-trends, the placebo in Table 4 reveals that even smaller (≤\$1B) banks improved more than controls after treatment, suggesting size-related trajectories. The authors attribute this to bias against detecting a deterrence effect, but they should more carefully test whether untreated banks within the \$3B–\$10B control group experienced contemporaneous shocks (e.g., differential exposure to CRE, regulatory changes, or macro shocks) that could confound the DiD. Including bank-specific time trends or weighting to balance observable characteristics, or employing synthetic control methods for robustness, would strengthen the identification.

**Suggestions**

1. **Quantify Policy Compliance and Treatment Intensity:**  
   - Provide evidence that banks identified as treated actually experienced an 18-month exam cycle post-2018. CDC releases occasionally list the exam frequency of banks; even if this is not publicly reported, aggregate FDIC or OCC schedules could help. Alternatively, survey data or press releases from regional agencies might confirm the timing.  
   - If exact exam dates cannot be observed, consider a fuzzy DiD: instrument treatment by eligibility (assets \$1–\$3B) but acknowledge imperfect compliance. Estimating first-stage changes in exam frequency or time between exams would substantiate the policy shock.

2. **Expand the Discussion on Mechanism and Alternative Channels:**  
   - The deterrence gap hinges on reduced detection probabilities translating into risk-taking. While market discipline and internal governance are plausible substitutes, the paper could strengthen the mechanism section by discussing alternative consequences of less frequent exams (e.g., more reliance on off-site monitoring, changes in exam intensity).  
   - Provide additional outcomes that perhaps capture behavioral responses—e.g., loan growth in higher-risk categories, changes in liquidity buffers, or measures of risk management expenses. Even if these are null, they help flesh out the incentive channel.

3. **Enhance Robustness to Size and Dynamics:**  
   - Estimate specifications that include bank-by-size (or bank-by-asset-bin) time trends to flexibly control for differential growth paths.  
   - Consider matching treated banks to controls on pre-trends in key outcomes or banking characteristics (capital, loan composition) to create a balanced sample before estimating the DiD.  
   - Explore alternative control groups such as banks just above \$3B but with similar asset growth or risk profiles, or even use triple-difference designs exploiting variation in CAMELS ratings (if available) to condition on internal health.

4. **Clarify the Placebo Interpretation:**  
   - The placebo result is intriguing but its interpretation is muddled. The authors argue the placebo reduction biases against finding a deterrence effect, yet they do not explain why banks below \$1B would improve more than \$3–\$10B banks. Is that due to size-driven competition, regulatory relief, or other policies? Clarifying the source of the placebo trend would help readers judge whether it genuinely represents a confound or an unrelated phenomenon.

5. **Address COVID and Macro Events More Fully:**  
   - The pandemic introduced substantial regulatory forbearance beginning in 2020. While excluding 2020–2021 is helpful, the authors might also consider interacting treatment with a COVID-era indicator to examine whether the deterrence gap materialized under stress.  
   - Explore whether treated banks and controls differed in their pandemic responses (PPP lending, CARES act participation). Differential exposure might offset or mask examination effects, so documenting these channels would improve narrative clarity.

6. **Report Full Event Study Coefficients and Confidence Bands:**  
   - The event study table currently lists only selected quarters, making it hard to assess the full dynamic pattern. Including a figure with confidence intervals (a standard event-study graph) would make the parallel trends claim more transparent.  
   - Additionally, report the number of observations per quarter to show whether sample composition changes over time (bank exit, mergers) might drive results.

7. **Discuss External Validity and Policy Trade-offs:**  
   - The conclusion suggests that well-run banks can absorb less supervision. It would be useful to discuss the boundary conditions of this finding (e.g., does it hold for banks near the systemic threshold, in different macro environments, or with lower CAMELS ratings?).  
   - Comparing the marginal cost savings from reduced exams with the statistical precision of the null effect would help policymakers assess whether the reform was worthwhile.  

**Conclusion:**  
The paper tackles an important policy question using a well-conceived natural experiment. Strengthening the discussion of treatment implementation, addressing potential dynamic confounders tied to bank size, and expanding robustness checks would greatly increase confidence in the null finding. Providing additional detail on the mechanism and including the suggested robustness exercises would keep the paper’s empirical strategy aligned with its research question and enhance its utility for policymakers.
